about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskDisease genes and chromosomes: disease maps of the human genome.Chromosome 12Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersRisk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.Genome-wide association studies of cancer.SGO White Paper on ovarian cancer: etiology, screening and surveillance.The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingInvasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.Identification of six new susceptibility loci for invasive epithelial ovarian cancer.Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy.Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative womenCommon breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.Hereditary ovarian cancer in Ashkenazi Jews.Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery.The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.Screening and prevention of hereditary gynecologic cancers.Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriersTamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.Genome-wide association studies of cancer predisposition.Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue.Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.
P50
Q21144874-53F1057A-3D95-40C4-ACA1-8D33DEF2BBC6Q27008356-AD48179D-C533-4E23-B62B-6A8FC28869AEQ28141806-09B84A6D-CAD1-49A3-84EA-E2504C7F9F5BQ30370475-D5ABD3C8-DAB3-402A-9149-826D0CF50371Q30374367-A3807607-5F9F-4FF3-95A8-14B5D018EBA4Q30416965-DDA094F3-9CBB-4779-8B98-B9FD39F6FEF2Q34129784-C32DF01D-2F19-45FD-919D-63497FCC844DQ34193988-0A6420FF-D1AA-425B-949B-8D200C2A32A0Q34622294-0A5A907F-90DB-4FD4-B764-3C80A5954E85Q34735951-FCD53210-F1A4-4559-A327-DD10D9727F44Q34749278-D7085C04-E128-4436-8CA2-9457F77FC84AQ35024008-188DB1E5-EBD8-4AF9-A032-5FFDC3297F0EQ35104225-10697D22-FC73-431C-B660-E64D4DAF1C8FQ35212074-0B6F41E9-90CC-4B37-A617-FBE7BE70EAF5Q35242849-4FED153F-3A4D-4E3E-9FDB-AC81C0F2E35BQ35541663-963B38DB-83BE-4473-9D27-668430E9DA75Q35674888-84CE4E20-2072-4D0E-A6E3-2E4BF175D228Q35846927-9EC21346-1C22-47A5-BD2D-D0998207248EQ35889575-EAB3385A-284A-4BC3-8907-9BDA0405BD81Q35934068-FB2BE284-7889-4D49-BF60-B781001B4268Q36158193-3F8BDED3-7DCD-431C-A3A9-A983530CED0CQ36260052-6A71C74C-B353-4094-8991-1001770A4553Q36375498-8ACF747F-45B2-4208-AB2F-D39656666F9BQ36763684-24B6FDE8-B056-4319-A0B6-E0009A20C91AQ36873066-FCFC85AF-B135-4586-9ABD-EEEC3E903060Q36916288-AA397AB0-D141-42BA-827D-F7A51885DE1FQ36963456-AF00DC3E-D076-4048-9CEB-54D02F1F61D7Q37010546-C5B4422A-042D-4A08-8542-C351436C8365Q37090813-ED1ACA74-F1A9-42C0-BB23-05C4CB260BB7Q37129654-F69569D2-5056-402B-B109-A0A49DAE5D0FQ37146082-666F0A6D-2B0B-4BCF-B746-4CC05C0A18B5Q37163464-06CD4073-BA28-4F32-BBD3-5AE93131AC59Q37540704-7F16A02B-7B01-4F28-8BF7-049B98DA0206Q37598435-2B102C72-9A01-46BD-A78D-E4F82C30A36FQ37785242-BEDEB55D-C4AB-4FE7-9D5E-42EB774ADD23Q37877648-5B5F00E2-20B1-4DB9-BB94-44607715467BQ37898483-A61382BC-5F4E-4F87-B6D4-515263FD59F5Q38437593-13DBEC26-E1EF-43BD-A0EA-A6074ECF0D60Q39816174-144715A3-006A-4ECD-8CDB-941A7C04E788Q40219523-53EFD6A5-BB0D-4667-BD2C-3678BDAD35D7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Noah Kauff
@ast
Noah Kauff
@en
Noah Kauff
@es
Noah Kauff
@nl
Noah Kauff
@sl
type
label
Noah Kauff
@ast
Noah Kauff
@en
Noah Kauff
@es
Noah Kauff
@nl
Noah Kauff
@sl
prefLabel
Noah Kauff
@ast
Noah Kauff
@en
Noah Kauff
@es
Noah Kauff
@nl
Noah Kauff
@sl
P106
P1153
6602695789
P21
P31
P496
0000-0001-7242-6156